The system will be used to treat plasma imported from countries with a reduced risk of vCJD transmission. Treated plasma will be used in the subsequent manufacture of paediatric and neonatal plasma components, and single and pooled cryoprecipitate. Approximate volume is 24000 plasma units per annum.
500, North Bristol Park, Filton
Published: 24 May 2017, Receipt by:
All suppliers that are registered with us receive email notifications of Public Sector tenders related to their area of business.